Eli Lilly Kelonia Acquisition Expands Genetic Medicine
Eli Lilly Kelonia acquisition broadens Lilly's oncology and genetic-medicine pipeline and may prompt investor reweighting of R&D focus.
KEY TAKEAWAYS
- Lilly agreed to acquire Kelonia to add an in vivo CAR-T program and gene-delivery platform.
- Deal includes $3.25 billion upfront and up to $7.0 billion in milestone-linked cash.
- Closing is expected in H2 2026 subject to customary regulatory approvals.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly’s acquisition of Kelonia Therapeutics, announced April 20, 2026, will add an in vivo CAR-T program and gene-delivery platform to its oncology pipeline. The multi-billion-dollar deal includes milestone-linked payments and broadens Lilly’s genetic-medicine capabilities.
Deal Terms and Timing
Eli Lilly (LLY) and Kelonia agreed to a cash acquisition valued at up to $7.0 billion, including a $3.25 billion upfront payment and additional milestone-based contingent payments. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals. Lilly will determine the GAAP accounting treatment at closing and incorporate the acquisition into its financial results and guidance thereafter.[source:3]
Kelonia Technology and Strategy
Kelonia Therapeutics is a privately held, Boston-based clinical-stage biotechnology company focused on an in vivo gene-delivery and integration platform. Its lead program, KLN-1010, is a Phase 1 lentiviral in vivo CAR-T therapy targeting relapsed or refractory multiple myeloma. Clinical data from KLN-1010 were highlighted at the 2025 ASH Annual Meeting plenary session.[source:3]
KLN-1010 aims to simplify CAR-T therapy by reprogramming a patient’s immune system to attack cancer cells while potentially avoiding chemotherapy and complex ex vivo cell manufacturing. Lilly described the acquisition as expanding its genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicability.[source:3]
